Synaptogenix Inc (SNPX)

[SF Wolf]

I have not examined Aphios' patent(s) for an analog compound of Byrostatin (it is not for Bryostatin-1).

My point was, in my post on Seeking Alpha (dkitt), that Aphios is still years behind NTRP in the regulatory process of getting a FDA approved drug to market and as Whatsupp just explained "in a recent talk by Dr Alkon, he said that NTRP patent covers any PK epsilon enhancing drug. I.e. Any company that sells such a drug has to go through them."